SCHEMBL6306459

SCHEMBL6306459

O=C1/C(=N/O)CCc2ccccc21

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.70
CYP1A2 P05177 1/20 0.70
CYP2C19 P33261 1/20 0.70
CES1 P23141 2/20 0.63
L3MBTL1 Q9Y468 3/20 0.56
HPGD P15428 2/20 0.56
LMNA P02545 1/20 0.53
HSD17B10 Q99714 1/20 0.53
TDP1 Q9NUW8 2/20 0.47
MAOA P21397 2/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
HTT P42858 1/20 0.46
MAOB P27338 2/20 0.46
MIF P14174 3/20 0.45
MAPT P10636 3/20 0.45
NPSR1 Q6W5P4 1/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
KMT2A Q03164 1/20 0.44
BCHE P06276 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL696955 1.00 ALDH1A1 (0.70) ALDH1A1CYP1A2CYP2C19CES1L3MBTL1
SCHEMBL7270862 1.00 ALDH1A1 (0.70) ALDH1A1CYP1A2CYP2C19CES1L3MBTL1
SCHEMBL2589100 0.89 L3MBTL1 (0.68) ALDH1A1CYP1A2CYP2C19CES1L3MBTL1
SCHEMBL2589102 0.89 L3MBTL1 (0.68) ALDH1A1CYP1A2CYP2C19CES1L3MBTL1
SCHEMBL2733083 0.84 HPGD (0.77) ALDH1A1CYP1A2CYP2C19CES1L3MBTL1
SCHEMBL29453066 0.84 HPGD (0.77) ALDH1A1CYP1A2CYP2C19CES1L3MBTL1
SCHEMBL1201521 0.84 HPGD (0.77) ALDH1A1CYP1A2CYP2C19CES1L3MBTL1
SCHEMBL1201517 0.84 HPGD (0.77) ALDH1A1CYP1A2CYP2C19CES1L3MBTL1
SCHEMBL29417938 0.84 HPGD (0.77) ALDH1A1CYP1A2CYP2C19CES1L3MBTL1
SCHEMBL2281246 0.82 ALDH1A1 (1.00) ALDH1A1CYP1A2CYP2C19CES1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000500-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2018-06-19 US disclosed
US-20180030059-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-02-01 US disclosed
US-8846277-B2 Compound, polymerizable composition, color filter, and method of producing the same, solid-state imaging device, and planographic printing plate precursor FUJIFILM CORPORATION (JP) 2014-09-30 US disclosed
WO-2014145512-A2 POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-09-18 WO disclosed
US-8703366-B2 2014-04-22 US disclosed
US-8569294-B2 2-(cyclic amino)-pyrimidone derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-10-29 US disclosed
US-20110267714-A1 NOVEL COMPOUND, POLYMERIZABLE COMPOSITION, COLOR FILTER, AND METHOD OF PRODUCING THE SAME, SOLID-STATE IMAGING DEVICE, AND PLANOGRAPHIC PRINTING PLATE PRECURSOR FUJIFILM CORPORATION (JP) 2011-11-03 US disclosed
US-20090233918-A1 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-09-17 US disclosed
US-6838455-B2 Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds ATHENA NEUROSCIENCES, INC. (US) 2005-01-04 US disclosed
US-20030149022-A1 Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds AUDIA JAMES E (US) 2003-08-07 US disclosed
US-6552013-B1 For therapy of Alzheimer's disease ELAN PHARMACEUTICALS, INC. 2003-04-22 US disclosed
EP-1089977-A1 COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS Elan Pharmaceuticals, Inc. (US) 2001-04-11 EP disclosed
WO-1999067219-A1 COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1999-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000500-B2 Coelenterazine analogues GLB1, TCF7L2, SI ALDH1A1 3416/4885CYP1A2 2617/4885CYP2C19 3378/4885
US-20110267714-A1 NOVEL COMPOUND, POLYMERIZABLE COMPOSITION, COLOR FILTER, AND METHOD OF PRODUCING THE SAME, SOLID-STATE IMAGING DEVICE, AND PLANOGRAPHIC PRINTING PLATE PRECURSOR SPOP, SMCHD1, PPOX ALDH1A1 1491/4885CYP1A2 713/4885CYP2C19 290/4885
US-20090233918-A1 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES MAPT, PRMT1, PSEN1 ALDH1A1 3952/4885CYP1A2 2460/4885CYP2C19 2411/4885
US-20030149022-A1 Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds APP, IAPP, BACE1 ALDH1A1 2282/4885CYP1A2 3996/4885CYP2C19 3267/4885
US-20180030059-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 ALDH1A1 3541/4885CYP1A2 2586/4885CYP2C19 3234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.